Brugada syndrome: An update

Future Cardiology

Volumn 9, Issue 2, 2013, Pages 253-271

  Li, Anthony ^a   Behr, Elijah R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Brugada syndrome; controversies; genetics; management; risk stratification

Indexed keywords

CILOSTAZOL; ISOPRENALINE; QUINIDINE;

ABLATION THERAPY; AUTONOMIC NERVOUS SYSTEM; BRUGADA SYNDROME; DEPOLARIZATION; ELECTROCARDIOGRAM; EPIDEMIOLOGY; EXERCISE TEST; FRAGMENTATION REACTION; GENDER; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEART ATRIUM ARRHYTHMIA; HEART DISEASE; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEREDITY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PATHOPHYSIOLOGY; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; REPOLARIZATION; REVIEW; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; ST SEGMENT ELEVATION; SUDDEN DEATH;

ANIMALS; ARRHYTHMIAS, CARDIAC; AUTONOMIC NERVOUS SYSTEM; BODY SURFACE POTENTIAL MAPPING; BRUGADA SYNDROME; CATHETER ABLATION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEART CONDUCTION SYSTEM; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84874685082     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.82     Document Type: Review

References (168)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J. Am. Coll. Cardiol. 20(6), 1391-1396 (1992).
2. Baron RC, Thacker SB, Gorelkin L, Vernon AA, Taylor WR, Choi K. Sudden death among southeast Asian refugees. An unexplained nocturnal phenomenon. JAMA 250(21), 2947-2951 (1983).
3. Vatta M, Dumaine R, Varghese G et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum. Mol. Genet. 11(3), 337-345 (2002).
4. Nademanee K, Veerakul G, Nimmannit S et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 96(8), 2595-2600 (1997).
5. Wilde AAM, Antzelevitch C, Borggrefe M et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 106(19), 2514-2519 (2002).
6. Antzelevitch C, Brugada P, Borggrefe M et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111(5), 659-670 (2005).
7. Holst AG, Tangø M, Batchvarov V et al. Specificity of elevated intercostal space ECG recording for the type 1 Brugada ECG pattern. Ann. Noninvasive Electrocardiol. 17(2), 108-112 (2012).
8. Chevallier S, Forclaz A, Tenkorang J et al. New electrocardiographic criteria for discriminating between Brugada types 2 and 3 patterns and incomplete right bundle branch block. J. Am. Coll. Cardiol. 58(22), 2290-2298 (2011).
9. Brugada P, Abdollah H, Heddle B, Wellens HJ. Results of a ventricular stimulation protocol using a maximum of 4 premature stimuli in patients without documented or suspected ventricular arrhythmias. Am. J. Cardiol. 52(10), 1214-1218 (1983).
10. Sarkozy A, Paparella G, Boussy T et al. The usefulness of the consensus clinical diagnostic criteria in Brugada syndrome. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.06.115 (2012) (Epub ahead of print).
11. Probst V, Veltmann C, Eckardt L et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation 121(5), 635-643 (2010).
12. Crotti L, Marcou CA, Tester DJ et al. Spectrum and prevalence of mutations involving BrS1-through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J. Am. Coll. Cardiol. 60(15), 1410-1418 (2012).
13. Shimizu W, Matsuo K, Takagi M et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eightyseven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J. Cardiovasc. Electrophysiol. 11(4), 396-404 (2000).
14. Govindan M, Batchvarov VN, Raju H et al. Utility of high and standard right precordial leads during ajmaline testing for the diagnosis of Brugada syndrome. Heart 96(23), 1904-1908 (2010).
15. Richter S, Sarkozy A, Paparella G et al. Number of electrocardiogram leads displaying the diagnostic coved-type pattern in Brugada syndrome: a diagnostic consensus criterion to be revised. Eur. Heart J. 31(11), 1357-1364 (2010).
16. Potet F, Mabo P, Le Coq G et al. Novel Brugada SCN5A mutation leading to ST segment elevation in the inferior or the right precordial leads. J. Cardiovasc. Electrophysiol. 14(2), 200-203 (2003).
17. Batchvarov VN, Govindan M, Camm AJ, Behr ER. Brugada-like changes in the peripheral leads during diagnostic ajmaline test in patients with suspected Brugada syndrome. Pacing Clin. Electrophysiol. 32(6), 695-703 (2009).
18. Sarkozy A, Chierchia GB, Paparella G et al. Inferior and lateral electrocardiographic repolarization abnormalities in Brugada syndrome. Circ. Arrhythmia Electrophysiol. 2(2), 154-161 (2009).
19. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J. Am. Coll. Cardiol. 27(5), 1061-1070 (1996).
20. Veltmann C, Wolpert C, Sacher F et al. Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges. Europace 11(10), 1345-1352 (2009).
21. Priori SG, Napolitano C, Gasparini M et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 102(20), 2509-2515 (2000).
22. Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AA, Tan HL. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J. Cardiovasc. Electrophysiol. 17(8), 857-864 (2006).
23. Hong K, Brugada J, Oliva A et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 110(19), 3023-3027 (2004).
24. Barra S, Providência R, Nascimento J. Fever outperforms flecainide test in the unmasking of type 1 Brugada syndrome electrocardiogram. Europace doi:10.1093/ europace/eus175 (2012) (Epub ahead of print).
25. Chiale PA, Przybylski J, Laiño RA et al. Electrocardiographic changes evoked by ajmaline in chronic Chagas' disease with manifest myocarditis. Am. J. Cardiol. 49(1), 14-20 (1982).
26. Peters S, Trümmel M, Denecke S, Koehler B. Results of ajmaline testing in patients with arrhythmogenic right ventricular dysplasia cardiomyopathy. Int. J. Cardiol. 95(2-3), 207-210 (2004).
27. Abello M, Merino JL, Peinado R, Gnoatto M. Negative flecainide test in Brugada syndrome patients with previous positive response. Europace 8(10), 899-900 (2006).
28. Wolpert C, Echternach C, Veltmann C et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2(3), 254-260 (2005).
29. Batchvarov VN, Govindan M, Camm AJ, Behr ER. Significance of QRS prolongation during diagnostic ajmaline test in patients with suspected Brugada syndrome. Heart Rhythm 6(5), 625-631 (2009).
30. Miyasaka Y, Tsuji H, Yamada K et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J. Am. Coll. Cardiol. 38(3), 771-774 (2001).
31. Matsuo K, Akahoshi M, Nakashima E et al. The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram. J. Am. Coll. Cardiol. 38(3), 765-770 (2001).
32. Gervacio-Domingo G, Isidro J, Tirona J et al. The Brugada type 1 electrocardiographic pattern is common among Filipinos. J. Clin. Epidemiol. 61(10), 1067-1072 (2008).
33. Gallagher MM, Forleo GB, Behr ER et al. Prevalence and significance of Brugada-type ECG in 12,012 apparently healthy European subjects. Int. J. Cardiol. 130(1), 44-48 (2008).
34. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J. Cardiovasc. Electrophysiol. 17(6), 577-583 (2006).
35. Antzelevitch C. Brugada syndrome. Pacing Clin. Electrophysiol. 29(10), 1130-1159 (2006).
36. Benito B, Sarkozy A, Mont L et al. Gender differences in clinical manifestations of Brugada syndrome. J. Am. Coll. Cardiol. 52(19), 1567-1573 (2008).
37. Behr ER, Dalageorgou C, Christiansen M et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. Eur. Heart J. 29(13), 1670-1680 (2008).
38. Papadakis M, Chandra N, Raju H et al. The diagnostic yield of Brugada syndrome in victims of sudden arrhythmic death syndrome; an underestimated entity? Eur. Heart J. 31(Suppl. 1), S841 (2010).
39. Brugada P. Commentary on the Brugada ECG pattern: a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome. Circ. Arrhythmia Electrophysiol. 3(3), 280-282 (2010).
40. Kapplinger JD, Tester DJ, Alders M et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 7(1), 33-46 (2010).
41. Heart Rhythm UK Familial Sudden Death Syndromes Statement Development Group. Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement. Heart 94(4), 502-507 (2008).
42. Ackerman MJ, Priori SG, Willems S et al. HRS/EHR A expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHR A). Europace 13(8), 1077-1109 (2011).
43. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation 123(9), 1021-1037 (2011).
44. Cotton RG, Scriver CR. Proof of 'disease-causing' mutation. Hum. Mutat. 12(1), 1-3 (1998).
45. Rook MB, Evers MM, Vos MA, Bierhuizen MF. Biology of cardiac sodium channel Nav1.5 expression. Cardiovasc. Res. 93(1), 12-23 (2012).
46. Chen Q, Kirsch GE, Zhang D et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392(6673), 293-296 (1998).
47. Dumaine R, Towbin JA, Brugada P et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ. Res. 85(9), 803-809 (1999).
48. Wang Q, Shen J, Splawski I et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80(5), 805-811 (1995).
49. Tan HL, Bink-Boelkens MT, Bezzina CR et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 409(6823), 1043-1047 (2001).
50. Benson DW, Wang DW, Dyment M et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest. 112(7), 1019-1028 (2003).
51. Darbar D, Kannankeril PJ, Donahue BS et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 117(15), 1927-1935 (2008).
52. Olson TM, Michels VV, Ballew JD et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 293(4), 447-454 (2005).
53. Makita N, Behr E, Shimizu W et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J. Clin. Invest. 118(6), 2219-2229 (2008).
54. Postema PG, Van den Berg M, Van Tintelen JP et al. Founder mutations in The Netherlands: SCN5A 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide. Neth. Heart J. 17(11), 422-428 (2009).
55. Probst V, Wilde AA, Barc J et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ. Cardiovasc. Genet. 2(6), 552-557 (2009).
56. Sakabe M, Fujiki A, Tsuneda T et al. Brugada syndrome occurring in an identical twin: a case report. J. Cardiol. 40(3), 111-115 (2002).
57. Meregalli PG, Tan HL, Probst V et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 6(3), 341-348 (2009).
58. Schulze-Bahr E, Eckardt L, Breithardt G et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum. Mutat. 21(6), 651-652 (2003).
59. London B, Michalec M, Mehdi H et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 116(20), 2260-2268 (2007).
60. Kattygnarath D, Maugenre S, Neyroud N et al. MOG1: a new susceptibility gene for Brugada syndrome. Circ. Cardiovasc. Genet. 4(3), 261-268 (2011).
61. Watanabe H, Koopmann TT, Le Scouarnec S et al. Sodium channel b1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J. Clin. Invest. 118(6), 2260-2268 (2008).
62. Hu D, Barajas-Martinez H, Burashnikov E et al. A mutation in the b3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ. Cardiovasc. Genet. 2(3), 270-278 (2009).
63. Antzelevitch C, Pollevick GD, Cordeiro JM et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 115(4), 442-449 (2007).
64. Burashnikov E, Pfeiffer R, Barajas-Martinez H et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 7(12), 1872-1882 (2010).
65. Delpón E, Cordeiro JM, Núñez L et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ. Arrhythmia Electrophysiol. 1(3), 209-218 (2008).
66. Giudicessi JR, Ye D, Tester DJ et al. Transient outward current (Ito) gain-offunction mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 8(7), 1024-1032 (2011).
67. Medeiros-Domingo A, Tan BH, Crotti L et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 7(10), 1466-1471 (2010).
68. Barajas-Martínez H, Hu D, Ferrer T et al. Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm 9(4), 548-555 (2012).
69. Koopmann TT, Beekman L, Alders M et al. Exclusion of multiple candidate genes and large genomic rearrangements in SCN5A in a Dutch Brugada syndrome cohort. Heart Rhythm 4(6), 752-755 (2007).
70. Antzelevitch C. The Brugada syndrome. J. Cardiovasc. Electrophysiol. 9(5), 513-516 (1998).
71. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 93(2), 372-379 (1996).
72. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100(15), 1660-1666 (1999).
73. Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 1(2), 210-217 (2004).
74. Nabauer M, Beuckelmann DJ, Uberfuhr P, Steinbeck G. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation 93(1), 168-177 (1996).
75. Kurita T, Shimizu W, Inagaki M et al. The electrophysiologic mechanism of STsegment elevation in Brugada syndrome. J. Am. Coll. Cardiol. 40(2), 330-334 (2002).
76. Nagase S, Kusano KF, Morita H et al. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: using the epicardial lead. J. Am. Coll. Cardiol. 39(12), 1992-1995 (2002).
77. Shimizu W, Aiba T, Kurita T, Kamakura S. Paradoxic abbreviation of repolarization in epicardium of the right ventricular outflow tract during augmentation of Brugada-type ST segment elevation. J. Cardiovasc. Electrophysiol. 12(12), 1418-1421 (2001).
78. Coronel R, Casini S, Koopmann TT et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 112(18), 2769-2777 (2005).
79. Meregalli PG, Wilde AAM, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc. Res. 67(3), 367-378 (2005).
80. Postema PG, van Dessel PF, Kors JA et al. Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in Brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation. J. Am. Coll. Cardiol. 55(8), 789-797 (2010).
81. Eckardt L, Bruns HJ, Paul M et al. Body surface area of ST elevation and the presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome. J. Cardiovasc. Electrophysiol. 13(8), 742-749 (2002).
82. Takami M, Ikeda T, Enjoji Y, Sugi K. Relationship between ST-segment morphology and conduction disturbances detected by signal-averaged electrocardiography in Brugada syndrome. Ann. Noninvasive Electrocardiol. 8(1), 30-36 (2003).
83. Tukkie R, Sogaard P, Vleugels J, de Groot IK, Wilde AA, Tan HL. Delay in right ventricular activation contributes to Brugada syndrome. Circulation 109(10), 1272-1277 (2004).
84. Rouzet F, Algalarrondo V, Burg S et al. Contraction delay of the RV outflow tract in patients with Brugada syndrome is dependent on the spontaneous ST-segment elevation pattern. Heart Rhythm 8(12), 1905-1912 (2011).
85. Postema PG, van Dessel PF, de Bakker JM et al. Slow and discontinuous conduction conspire in Brugada syndrome: a right ventricular mapping and stimulation study. Circ. Arrhythmia Electrophysiol. 1(5), 379-386 (2008).
86. Lambiase PD, Ahmed AK, Ciaccio EJ et al. High-density substrate mapping in Brugada syndrome: combined role of conduction and repolarization heterogeneities in arrhythmogenesis. Circulation 120(2), 106-117, 1-4 (2009).
87. Nademanee K, Veerakul G, Chandanamattha P et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 123(12), 1270-1279 (2011).
88. Catalano O, Antonaci S, Moro G et al. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. Eur. Heart J. 30(18), 2241-2248 (2009).
89. Nishii N, Nagase S, Morita H et al. Abnormal restitution property of action potential duration and conduction delay in Brugada syndrome: both repolarization and depolarization abnormalities. Europace 12(4), 544-552 (2010).
90. Papavassiliu T, Wolpert C, Flüchter S et al. Magnetic resonance imaging findings in patients with Brugada syndrome. J. Cardiovasc. Electrophysiol. 15(10), 1133-1138 (2004).
91. Zumhagen S, Spieker T, Rolinck J et al. Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada syndrome. Circ. Arrhythmia Electrophysiol. 2(1), 16-23 (2009).
92. Frustaci A, Priori SG, Pieroni M et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation 112(24), 3680-3687 (2005).
93. Ohkubo K, Watanabe I, Okumura Y et al. Right ventricular histological substrate and conduction delay in patients with Brugada syndrome. Int. Heart J. 51(1), 17-23 (2010).
94. Tarín N, Farré J, Rubio JM, Tuñón J, Castro-Dorticós J. Brugada-like electrocardiographic pattern in a patient with a mediastinal tumor. Pacing Clin. Electrophysiol. 22(8), 1264-1266 (1999).
95. Royer A, van Veen TAB, Le Bouter S et al. Mouse model of SCN5A-linked hereditary Lenègre's disease: age-related conduction slowing and myocardial fibrosis. Circulation 111(14), 1738-1746 (2005).
96. Kolder IC, Tanck MW, Bezzina CR. Common genetic variation modulating cardiac ECG parameters and susceptibility to sudden cardiac death. J. Mol. Cell. Cardiol. 52(3), 620-629 (2012).
97. Bezzina CR, Shimizu W, Yang P et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 113(3), 338-344 (2006).
98. Ohno S, Zankov DP, Ding WG et al. KCNE5 (KCNE1L) variants are novel modulators of Brugada syndrome and idiopathic ventricular fibrillation. Circ. Arrhythmia Electrophysiol. 4(3), 352-361 (2011).
99. Eckardt L. Gender differences in Brugada syndrome. J. Cardiovasc. Electrophysiol. 18(4), 422-424 (2007).
100. Di Diego JM. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 106(15), 2004-2011 (2002).
101. Ezaki K, Nakagawa M, Taniguchi Y et al. Gender differences in the ST segment: effect of androgen-deprivation therapy and possible role of testosterone. Circ. J. 74(11), 2448-2454 (2010).
102. Matsuo K, Akahoshi M, Seto S, Yano K. Disappearance of the Brugada-type electrocardiogram after surgical castration: a role for testosterone and an explanation for the male preponderance. Pacing Clin. Electrophysiol. 26(7 Pt 1), 1551-1553 (2003).
103. Shimizu W, Matsuo K, Kokubo Y et al. Sex hormone and gender difference -role of testosterone on male predominance in Brugada syndrome. J. Cardiovasc. Electrophysiol. 18(4), 415-421 (2007).
104. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 112(12), 1701-1710 (2005).
105. Liu XK, Katchman A, Whitfield BH et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc. Res. 57(1), 28-36 (2003).
106. Matsuo K, Kurita T, Inagaki M et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur. Heart J. 20(6), 465-470 (1999).
107. Takigawa M, Noda T, Shimizu W et al. Seasonal and circadian distributions of ventricular fibrillation in patients with Brugada syndrome. Heart Rhythm 5(11), 1523-1527 (2008).
108. Kim SH, Nam GB, Baek S et al. Circadian and seasonal variations of ventricular tachyarrhythmias in patients with early repolarization syndrome and Brugada syndrome: analysis of patients with implantable cardioverter defibrillator. J. Cardiovasc. Electrophysiol. 23(7), 757-763 (2012).
109. Ikeda T, Abe A, Yusu S et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J. Cardiovasc. Electrophysiol. 17(6), 602-607 (2006).
110. Mizumaki K, Fujiki A, Tsuneda T et al. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J. Cardiovasc. Electrophysiol. 15(6), 667-673 (2004).
111. Abe A, Kobayashi K, Yuzawa H et al. Comparison of late potentials for 24 hours between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy using a novel signal-averaging system based on Holter electrocardiogram. Circ. Arrhythmia Electrophysiol. 5(4), 789-795 (2012).
112. Ohgo T, Okamura H, Noda T et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 4(6), 695-700 (2007).
113. Omiya T, Shimizu A, Ueyama T et al. Effects of isoproterenol and propranolol on the inducibility and frequency of ventricular fibrillation in patients with Brugada syndrome. J. Cardiol. 60(1), 47-54 (2012).
114. Kostopoulou A, Koutelou M, Theodorakis G et al. Disorders of the autonomic nervous system in patients with Brugada syndrome: a pilot study. J. Cardiovasc. Electrophysiol. 21(7), 773-780 (2010).
115. Bigi MA, Aslani A, Aslani A. Significance of cardiac autonomic neuropathy in risk stratification of Brugada syndrome. Europace 10(7), 821-824 (2008).
116. Wichter T, Matheja P, Eckardt L et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 105(6), 702-706 (2002).
117. Kies P, Wichter T, Schäfers M et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation 110(19), 3017-3022 (2004).
118. Paul M, Meyborg M, Boknik P et al. Autonomic dysfunction in patients with Brugada syndrome: further biochemical evidence of altered signaling pathways. Pacing Clin. Electrophysiol. 34(9), 1147-1153 (2011).
119. Garratt CJ, Elliott P, Behr E et al. Heart rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 12(8), 1156-1175 (2010).
120. Brugada J. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 105(1), 73-78 (2002).
121. Veltmann C, Schimpf R, Echternach C et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur. Heart J. 27(21), 2544-2552 (2006).
122. Richter S, Sarkozy A, Veltmann C et al. Variability of the diagnostic ECG pattern in an ICD patient population with Brugada syndrome. J. Cardiovasc. Electrophysiol. 20(1), 69-75 (2009).
123. Shimeno K, Takagi M, Maeda K, Tatsumi H, Doi A, Yoshiyama M. Usefulness of multichannel Holter ECG recording in the third intercostal space for detecting type 1 Brugada ECG: comparison with repeated 12-lead ECGs. J. Cardiovasc. Electrophysiol. 20(9), 1026-1031 (2009).
124. Yokokawa M, Okamura H, Noda T et al. Neurally mediated syncope as a cause of syncope in patients with Brugada electrocardiogram. J. Cardiovasc. Electrophysiol. 21(2), 186-192 (2010).
125. Sacher F, Arsac F, Wilton SB et al. Syncope in Brugada syndrome patients: prevalence, characteristics, and outcome. Heart Rhythm 9(8), 1272-1279 (2012).
126. Kubala M, Aïssou L, Traullé S, Gugenheim AL, Hermida JS. Use of implantable loop recorders in patients with Brugada syndrome and suspected risk of ventricular arrhythmia. Europace 14(6), 898-902 (2011).
127. Sarkozy A, Sorgente A, Boussy T et al. The value of a family history of sudden death in patients with diagnostic type I Brugada ECG pattern. Eur. Heart J. 32(17), 2153-2160 (2011).
128. Priori SG. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 105(11), 1342-1347 (2002).
129. Paul M, Gerss J, Schulze-Bahr E et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: a metaanalysis of worldwide published data. Eur. Heart J. 28(17), 2126-2133 (2007).
130. Kamakura S, Ohe T, Nakazawa K et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ. Arrhythmia Electrophysiol. 2(5), 495-503 (2009).
131. Priori SG, Gasparini M, Napolitano C et al. Risk stratification in Brugada syndrome results of the PRELUDE (Programmed Electrical Stimulation Predictive Value) Registry. J. Am. Coll. Cardiol. 59(1), 37-45 (2012).
132. Viskin S, Rogowski O. Asymptomatic Brugada syndrome: a cardiac ticking timebomb? Europace 9(9), 707-710 (2007).
133. Raju H, Papadakis M, Govindan M et al. Low prevalence of risk markers in cases of sudden death due to Brugada syndrome relevance to risk stratification in Brugada syndrome. J. Am. Coll. Cardiol. 57(23), 2340-2345 (2011).
134. Delise P, Allocca G, Marras E et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur. Heart J. 32(2), 169-176 (2011).
135. Huang Z, Patel C, Li W et al. Role of signalaveraged electrocardiograms in arrhythmic risk stratification of patients with Brugada syndrome: a prospective study. Heart Rhythm 6(8), 1156-1162 (2009).
136. Ikeda T, Takami M, Sugi K, Mizusawa Y, Sakurada H, Yoshino H. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Ann. Noninvasive Electrocardiol. 10(4), 396-403 (2005).
137. Tatsumi H, Takagi M, Nakagawa E, Yamashita H, Yoshiyama M. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG). J. Cardiovasc. Electrophysiol. 17(7), 705-711 (2006).
138. Morita H, Kusano KF, Miura D et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 118(17), 1697-1704 (2008).
139. Josephson ME. Electrophysiologic investigation: general concepts. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations (4th Edition). Lippincott Williams & Wilkins, PA, USA (2008).
140. Makimoto H, Nakagawa E, Takaki H et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. J. Am. Coll. Cardiol. 56(19), 1576-1584 (2010).
141. Amin AS, de Groot EA, Ruijter JM, Wilde AA, Tan HL. Exercise-induced ECG changes in Brugada syndrome. Circ. Arrhythmia Electrophysiol. 2(5), 531-539 (2009).
142. Bastiaenen R, Behr ER. Early repolarisation: controversies and clinical implications. Heart 98(11), 841-847 (2012).
143. Letsas KP, Sacher F, Probst V et al. Prevalence of early repolarization pattern in inferolateral leads in patients with Brugada syndrome. Heart Rhythm 5(12), 1685-1689 (2008).
144. Muggenthaler M, Behr ER. Brugada syndrome and atrial fibrillation: pathophysiology and genetics. Europace 13(7), 913-915 (2011).
145. Kusano KF, Taniyama M, Nakamura K et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J. Am. Coll. Cardiol. 51(12), 1169-1175 (2008).
146. Sacher F, Probst V, Iesaka Y et al. Outcome after implantation of a cardioverterdefibrillator in patients with Brugada syndrome: a multicenter study. Circulation 114(22), 2317-2324 (2006).
147. Sarkozy A, Boussy T, Kourgiannides G et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur. Heart J. 28(3), 334-344 (2007).
148. Steven D, Roberts-Thomson KC, Inada K et al. Long-term follow-up in patients with presumptive Brugada syndrome treated with implanted defibrillators. J. Cardiovasc. Electrophysiol. 22(10), 1115-1119 (2011).
149. Kumar S, Kalman JM, Sutherland F, Spence SJ, Finch S, Sparks PB. Atrial fibrillation inducibility in the absence of structural heart disease or clinical atrial fibrillation: critical dependence on induction protocol, inducibility definition, and number of inductions. Circ. Arrhythmia Electrophysiol. 5(3), 531-536 (2012).
150. Veltmann C, Kuschyk J, Schimpf R et al. Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin. Res. Cardiol. 99(1), 37-44 (2010).
151. Postema PG, Wolpert C, Amin AS et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www. brugadadrugs.org). Heart Rhythm 6(9), 1335-1341 (2009).
152. Cappato R, Smith WM, Hood MA et al. Subcutaneous chronic implantable defibrillation systems in humans. J. Int. Cardiac Electrophysiol. 34(3), 325-332 (2012).
153. Hermida JS, Denjoy I, Clerc J et al. Hydroquinidine therapy in Brugada syndrome. J. Am. Coll. Cardiol. 43(10), 1853-1860 (2004).
154. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110(13), 1731-1737 (2004).
155. Mizusawa Y, Sakurada H, Nishizaki M, Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment. J. Cardiovasc. Pharmacol. 47(3), 359-364 (2006).
156. Mok NS, Chan NY, Chiu ACS. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin. Electrophysiol. 27(6 Pt 1), 821-823 (2004).
157. Márquez MF, Bonny A, Hernández-Castillo E et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 9(12), 1995-2000 (2012).
158. Viskin S, Antzelevitch C, Márquez MF, Belhassen B. Quinidine: a valuable medication joins the list of 'endangered species'. Europace 9(12), 1105-1106 (2007).
159. Kyriazis K, Bahlmann E, van der Schalk H, Kuck KH. Electrical storm in Brugada syndrome successfully treated with orciprenaline; effect of low-dose quinidine on the electrocardiogram. Europace 11(5), 665-666 (2009).
160. Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J. Cardiovasc. Electrophysiol. 13(7), 698-701 (2002).
161. Abud A, Bagattin D, Goyeneche R, Becker C. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J. Cardiovasc. Electrophysiol. 17(2), 210-212 (2006).
162. Haïssaguerre M, Extramiana F, Hocini M et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 108(8), 925-928 (2003).
163. Nakagawa E, Takagi M, Tatsumi H, Yoshiyama M. Successful radiofrequency catheter ablation for electrical storm of ventricular fibrillation in a patient with Brugada syndrome. Circ. J. 72(6), 1025-1029 (2008).
164. Darmon JP, Bettouche S, Deswardt P et al. Radiofrequency ablation of ventricular fibrillation and multiple right and left atrial tachycardia in a patient with Brugada syndrome. J. Int. Cardiac Electrophysiol. 11(3), 205-209 (2004).
165. Shah AJ, Hocini M, Lamaison D, Sacher F, Derval N, Haissaguerre M. Regional substrate ablation abolishes Brugada syndrome. J. Cardiovasc. Electrophysiol. 22(11), 1290-1291 (2011).
166. Roberts-Thomson KC, Seiler J, Steven D et al. Percutaneous access of the epicardial space for mapping ventricular and supraventricular arrhythmias in patients with and without prior cardiac surgery. J. Cardiovasc. Electrophysiol. 21(4), 406-411 (2010).
167. Empiric quinidine for asymptomatic Brugada syndrome. http:// clinicaltrials.gov/ct2/show/ NCT00789165
168. Hydroquinidine versus placebo in patients with Brugada syndrome (Quidam). http://clinicaltrials.gov/ct2/show/ NCT00927732